A very disappointing update.
N.L is commercially underperforming and well behind expectations.
Imo the company needs change and change should start at the top.
Staff were released until we got additional capital which appears to be impacting our growth.
The cap raise has been fumbled for almost a year and still not complete.
A.I. and Med Tech are the 'flavour of the month' sectors and raising funds in this area should be straight forward, especially for a company with presence in USA, EU & Asia.
Playing around with retail aussie brokers isn't the way to go imo. The money raised recently costs us 15% p.a -plus- likely dilution. This smells of desperation.
Imo we need immediate change to avoid large dilution or potentially going under.
